Shares in liver and cardio-metabolic specialist 89bio (Nasdaq: ETNB) were up 5% ahead of the opening bell on Friday, following positive Phase II results from the ENTRIGUE study.
The San Franciscan firm is developing pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), as an option for severe hypertriglyceridemia (SHG).
Data showing the proof-of-concept trial met its primary efficacy endpoint will be presented at the annual meeting of the European Society of Cardiology in the coming days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze